All factors have been reflected in the price

2021-09-09

There is a lot of game changing therapies coming in the hematological & BMT space. Just two off the bat are GMDA and ANTM, both still clinical stage companies but possible game changes which would reduce the % of allograft BMT procedures from relatives & donor pool to using more chord blood (GMDA's approach ) since it inherently has far less GVHD issues that donor marrow. Then ATNM has a therapy to improve conditioning thru targeted radiation vs chemo that if the FDA approves will make the tradition Allo BMT obsolete and KDMN meaningless. KMDN could have a relatively short window as a result so smart for Waksal bros to take the money and run into retirement. Sanofi realizes this too so that's factored into their price for sure..

Congrats to the longs!!!$Kadmon(KDMN)$

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":889734120,"tweetId":"889734120","gmtCreate":1631177535058,"gmtModify":1676530488246,"author":{"id":9000000000000202,"idStr":"9000000000000202","authorId":9000000000000202,"authorIdStr":"9000000000000202","name":"zubee","avatar":"https://static.tigerbbs.com/b610f7fa83d7281fe00c102df34d1691","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":40,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"All factors have been reflected in the price","extraTitle":"","html":"<html><head></head><body>There is a lot of game changing therapies coming in the hematological &amp; BMT space. Just two off the bat are GMDA and ANTM, both still clinical stage companies but possible game changes which would reduce the % of allograft BMT procedures from relatives &amp; donor pool to using more chord blood (GMDA's approach ) since it inherently has far less GVHD issues that donor marrow. Then ATNM has a therapy to improve conditioning thru targeted radiation vs chemo that if the FDA approves will make the tradition Allo BMT obsolete and KDMN meaningless. KMDN could have a relatively short window as a result so smart for Waksal bros to take the money and run into retirement. Sanofi realizes this too so that's factored into their price for sure.. Congrats to the longs!!!<a href=\"https://laohu8.com/S/KDMN\">$Kadmon(KDMN)$</a> </body></html>","htmlText":"<html><head></head><body>There is a lot of game changing therapies coming in the hematological &amp; BMT space. Just two off the bat are GMDA and ANTM, both still clinical stage companies but possible game changes which would reduce the % of allograft BMT procedures from relatives &amp; donor pool to using more chord blood (GMDA's approach ) since it inherently has far less GVHD issues that donor marrow. Then ATNM has a therapy to improve conditioning thru targeted radiation vs chemo that if the FDA approves will make the tradition Allo BMT obsolete and KDMN meaningless. KMDN could have a relatively short window as a result so smart for Waksal bros to take the money and run into retirement. Sanofi realizes this too so that's factored into their price for sure.. Congrats to the longs!!!<a href=\"https://laohu8.com/S/KDMN\">$Kadmon(KDMN)$</a> </body></html>","text":"There is a lot of game changing therapies coming in the hematological & BMT space. Just two off the bat are GMDA and ANTM, both still clinical stage companies but possible game changes which would reduce the % of allograft BMT procedures from relatives & donor pool to using more chord blood (GMDA's approach ) since it inherently has far less GVHD issues that donor marrow. Then ATNM has a therapy to improve conditioning thru targeted radiation vs chemo that if the FDA approves will make the tradition Allo BMT obsolete and KDMN meaningless. KMDN could have a relatively short window as a result so smart for Waksal bros to take the money and run into retirement. Sanofi realizes this too so that's factored into their price for sure.. Congrats to the longs!!!$Kadmon(KDMN)$","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/889734120","repostId":0,"isVote":1,"tweetType":1,"viewCount":611,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["KDMN"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":645,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/889734120"}